OverviewSuggest Edit

NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. It markets its proprietary therapy, Tumor Treating Fields, that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die. Tumor Treating Fields is used as a monotherapy treatment for adult patients with glioblastoma brain cancer and malignant pleural mesothelioma. The company is also involved in conducting clinical trials for the use of Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and gastric cancer.

TypePublic
Founded2000
HQSaint Helier, JE
Websitenovocure.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2020)1,023(+31%)
Job Openings52
Revenue (FY, 2020)$494.4 M(+41%)
Share Price (May 2021)$175(-2%)
Cybersecurity ratingBMore

Key People/Management at NovoCure

Asaf Danziger

Asaf Danziger

Chief Executive Officer, Director
William F. Doyle

William F. Doyle

Executive Chairman
Yoram Palti

Yoram Palti

Founder
Ely Benaim

Ely Benaim

Chief Medical Officer
Todd Longsworth

Todd Longsworth

General Counsel
Pritesh Shah

Pritesh Shah

Chief Commercial Officer
Show more

NovoCure Office Locations

NovoCure has offices in Saint Helier, Malvern, New York, Portsmouth and in 4 other locations
Saint Helier, JE (HQ)
Second Floor, No. 4 The Forum, Grenville Street
München, DE
Elektrastraße 6
Haifa, IL
Topaz Building 4th Floor MATAM Center Sha’ar HaCarmel
Chiyoda City, JP
tower 36th floor, 1-chōme-9-1 Marunouchi
Root, CH
Park 6 CH-6039
Malvern, PA, US
20 Valley Stream Pkwy #300
Show all (8)

NovoCure Financials and Metrics

NovoCure Revenue

Embed Graph
View revenue for all periods
NovoCure's revenue was reported to be $494.37 m in FY, 2020 which is a 40.7% increase from the previous period.
USD

Revenue (Q1, 2021)

134.7m

Gross profit (Q1, 2021)

108.3m

Gross profit margin (Q1, 2021), %

80.4%

Net income (Q1, 2021)

(4.1m)

EBIT (Q1, 2021)

(88.0k)

Market capitalization (17-May-2021)

18.1b

Closing stock price (17-May-2021)

175.0

Cash (31-Mar-2021)

314.5m

EV

18.4b
NovoCure's current market capitalization is $18.1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

248.1m351.3m494.4m

Revenue growth, %

42%41%

Cost of goods sold

80.0m88.6m106.5m

Gross profit

168.0m262.7m387.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

52.1m61.5m64.8m73.3m86.7m92.1m101.8m115.9m132.7m134.7m

Cost of goods sold

18.2m19.8m18.9m19.8m21.1m22.9m24.5m25.5m28.4m26.4m

Gross profit

33.9m41.7m45.8m53.5m65.6m69.2m77.3m90.5m104.3m108.3m

Gross profit Margin, %

65%68%71%73%76%75%76%78%79%80%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

140.6m177.3m234.7m

Accounts Receivable

36.5m58.9m96.7m

Inventories

22.6m23.7m27.4m

Current Assets

321.4m439.9m999.4m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(63.6m)(7.2m)19.8m

Depreciation and Amortization

9.0m8.5m9.2m

Inventories

(529.0k)(1.2m)(2.9m)

Accounts Payable

9.5m16.9m25.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(20.7m)(36.2m)(47.9m)(12.1m)(13.4m)(11.5m)4.0m5.6m14.9m(4.1m)

Depreciation and Amortization

2.2m4.5m6.8m1.9m4.1m6.0m1.9m4.5m6.7m2.4m

Inventories

1.6m2.1m385.0k(1.6m)(2.9m)(1.8m)1.1m(2.4m)(2.4m)(1.3m)

Accounts Payable

2.2m3.2m2.8m3.2m3.4m10.9m(2.3m)(1.9m)8.0m(2.6m)
USDQ1, 2018

Debt/Equity

1.4 x

Debt/Assets

0.5 x

Financial Leverage

2.9 x
Show all financial metrics

NovoCure Operating Metrics

FY, 2018FY, 2019FY, 2020May, 2021

Patents and Patent Applications

140180185

Phase II Trials Products

2232

Phase III Trials Products

3454

Trials Products Approved

13
Show all operating metrics

NovoCure Acquisitions / Subsidiaries

Company NameDateDeal Size
Novocure Austria GmbH
Novocure Canada, Inc.
Novocure Capital
Novocure France SAS
Novocure GmbH
NovoCure GmbH
Novocure Inc.
NovoCure (Israel) Ltd.
Novocure K.K.
Novocure Luxembourg S.à.r.l.
Show more

NovoCure Revenue Breakdown

Embed Graph

NovoCure revenue breakdown by geographic segment: 68.9% from United States, 18.9% from Germany, 5.9% from Japan and 6.3% from Other

NovoCure Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

NovoCure Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

NovoCure Online and Social Media Presence

Embed Graph

NovoCure News and Updates

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven by COVID-19, as well as continued progress across the company’s clinical and product development progra…

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also announced th…

Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC), Novocur…

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Research spanning seven solid tumor ty…

Novocure to Report First Quarter 2021 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended Marc…

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

SHANGHAI, China and ST. HELIER, Jersey, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treatin…
Show more

NovoCure Blogs

Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

IDE supplement incorporates recommended changes from the interim analysis of the LUNAR trial conducted by an independent data monitoring committee ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investi…

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today report…

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, N…

Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NAS…

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Res…

Novocure to Report First Quarter 2021 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial resu…
Show more

NovoCure Frequently Asked Questions

  • When was NovoCure founded?

    NovoCure was founded in 2000.

  • Who are NovoCure key executives?

    NovoCure's key executives are Asaf Danziger, William F. Doyle and Yoram Palti.

  • How many employees does NovoCure have?

    NovoCure has 1,023 employees.

  • What is NovoCure revenue?

    Latest NovoCure annual revenue is $494.4 m.

  • What is NovoCure revenue per employee?

    Latest NovoCure revenue per employee is $483.3 k.

  • Who are NovoCure competitors?

    Competitors of NovoCure include Silverback Therapeutics, Sensei Biotherapeutics and Accuray.

  • Where is NovoCure headquarters?

    NovoCure headquarters is located at Second Floor, No. 4 The Forum, Grenville Street, Saint Helier.

  • Where are NovoCure offices?

    NovoCure has offices in Saint Helier, Malvern, New York, Portsmouth and in 4 other locations.

  • How many offices does NovoCure have?

    NovoCure has 8 offices.